| Literature DB >> 32301287 |
Sang Chul Lee1, Eun Young Kim2, Joon Chang2, Sang Hoon Lee2, Chang Hoon Han1.
Abstract
BACKGROUND: Although the use of radial endobronchial ultrasound (R-EBUS) with a guide sheath has shown improved diagnostic capability in peripheral pulmonary lesions, its utility is still low due to variable performance. To overcome its limitation, we evaluated the feasibility and efficacy of R-EBUS combined with transbronchial biopsy (TBB) under fluoroscopic guidance.Entities:
Keywords: Biopsy; bronchoscopy; fluoroscopy; lung cancer
Mesh:
Year: 2020 PMID: 32301287 PMCID: PMC7262934 DOI: 10.1111/1759-7714.13425
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.500
Figure 1Case of a 74‐year‐old man with a consolidation in the right lower lobe.(a) Chest X‐ray showing consolidation at the right lower lobe. (b) Computed tomography (CT) scan showing a 38 mm peripheral lung mass. (c) Radial probe endobronchial ultrasound (R‐EBUS) in the lateral basilar segment of the right lower lobe revealing a mixed blizzard sign containing a heterogeneous acoustic shadow with hyperechoic dots, linear arcs, and vessels. (d) Fluoroscopic image during transbronchial biopsy through a guide sheath.
Patient and lesion characteristics
| Variable | All subjects | Standard TBB | R‐EBUS‐TBB |
|
|---|---|---|---|---|
| Male sex | 42 (37.8) | 21 (56.8) | 21 (56.8) | 1.000 |
| Age | 67.4 ± 12.8 | 67.3 ± 12.8 | 67.5 ± 13.0 | 0.808 |
| Ever‐smoker | 28 (56.7) | 21 (56.8) | 17 (45.9) | 0.486 |
| Comorbidities | ||||
| Hypertension | 27 (36.4) | 14 (37.8) | 13 (35.1) | 1.000 |
| Diabetes | 12 (16.2) | 8 (21.6) | 4 (10.8) | 0.345 |
| Old CVA | 2 (2.7) | 1 (2.7) | 1 (2.7) | 1.000 |
| Old Tbc | 10 (13.5) | 7 (18.9) | 3 (8.1) | 0.308 |
| COPD | 6 (8.1) | 3 (8.1) | 3 (8.1) | 1.000 |
| Asthma | 4 (5.4) | 2 (5.4) | 2 (5.4) | 1.000 |
| Other malignancies | 16 (21.6) | 9 (24.3) | 7 (18.9) | 0.778 |
| Tumor markers | ||||
| CEA | 26.4 ± 83.8 | 35.7 ± 95.7 | 19.2 ± 73.9 | 0.447 |
| Cyfra 21–1 | 3.0 ± 1.9 | 2.9 ± 1.4 | 3.1 ± 2.2 | 0.856 |
| Procedure duration (minutes) | 42.9 ± 16.4 | 38.1 ± 16.2 | 47.6 ± 15.3 | 0.743 |
| Location of PPL(s) | 1.000 | |||
| RUL | 16 (21.6) | 8 (21.6) | 8 (21.6) | |
| RML | 6 (8.1) | 3 (8.1) | 3 (8.1) | |
| RLL | 20 (27.0) | 10 (27.0) | 10 (27.0) | |
| LUL | 22 (29.7) | 11 (29.7) | 11 (29.7) | |
| LLL | 10 (13.5) | 5 (13.5) | 5 (13.5) | |
| Nodule type | 0.193 | |||
| Solid | 53 (71.6) | 26 (70.3) | 27 (73.0) | |
| Subsolid | 15 (20.2) | 6 (16.2) | 9 (24.3) | |
| GGO | 6 (8.1) | 5 (13.5) | 1 (2.7) | |
| Air‐bronchus sign | 32 (43.2) | 18 (48.6) | 14 (37.8) | 0.241 |
| Size, mean (mm) | 28.7 ± 13.2 | 34.5 ± 15.5 | 23.6 ± 7.6 | < 0.001 |
| < 20 | 20 (27.0) | 7 (18.9) | 13 (35.1) | |
| 20–30 | 28 (37.8) | 11 (29.7) | 17 (45.9) | |
| > 30 | 26 (35.1) | 19 (51.4) | 7 (18.9) | |
| Pleural distance (mm) | 12.5 ± 12.7 | 10.3 ± 10.5 | 14.8 ± 14.4 | 0.102 |
Significant differences (P < 0.05). CEA, carcinoembryonic antigen; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; GGO, ground‐glass opacity; LLL, left lower lobe; LUL, left upper lobe; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe; TBB, transbronchial biopsy; Tbc, tuberculosis.
Figure 2Schematic figure of diagnostic yield in two groups. * R‐EBUS, radial probe endobronchial ultrasound; TBB, transbronchial biopsy.
Univariate and multivariate analysis for predictors of diagnostic yield
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Variable | OR (95% CI) |
| OR (95% CI) |
|
| Solid nodule | 0.49 (0.15–1.56) | 0.223 | ||
| Nodule size ≥30 mm | 0.72 (0.27–1.95) | 0.526 | ||
| Air‐bronchus sign | 3.30 (1.21–9.00) | 0.017 | 3.52 (1.17–10.62) | 0.025 |
| Cavitation | 0.82 (0.21–3.24) | 0.783 | ||
| Pleural distance >20 mm | 0.65 (0.18–2.34) | 1.000 | ||
| R‐EBUS arm | 1.27 (0.48–3.33) | 0.624 | ||
Significant differences (P < 0.05). CI, confidence interval; OR, odds ratio; R‐EBUS, radial endobronchial ultrasound.
Bronchoscopic diagnosis
| Diagnosis | Total, No. (%) | Standard TBB, No. (%) | R‐EBUS‐TBB, No. (%) |
|---|---|---|---|
| Diagnostic | 49 (66.2) | 22 (59.4) | 27 (72.9) |
| Adenocarcinoma | 43 (58.1) | 19 (51.3) | 24 (64.8) |
| Squamous cell cancer | 2 (2.7) | 1 (2.7) | 1 (2.7) |
| Small cell cancer | 1 (1.3) | 0 (0.0) | 1 (2.7) |
| Large cell cancer | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Metastasis | 3 (4.0) | 2 (5.4) | 1 (2.7) |
| Nondiagnostic | 25 (33.7) | 15 (40.5) | 10 (37.0) |
| Biopsy failure | 19 (25.6) | 11 (29.7) | 8 (21.6) |
| Inflammation | 4 (5.4) | 2 (5.4) | 2 (5.4) |
| Granuloma | 1 (1.3) | 1 (2.7) | 0 (0.0) |
| Pneumonia | 1 (1.3) | 1 (2.7) | 0 (0.0) |
R‐EBUS, radial endobronchial ultrasound; TBB, transbronchial biopsy.
Complications of each procedure
| Complications | Total, No. (%) | Standard TBB, No. (%) | R‐EBUS‐TBB, No. (%) |
|
|---|---|---|---|---|
| Hemoptysis | 2 (2.7) | 1 (2.7) | 1 (2.7) | 0.667 |
| Pneumothorax | 3 (4.0) | 1 (2.7) | 2 (5.4) | 0.750 |
| Fever | 3 (4.0) | 1 (2.7) | 2 (5.4) | 0.600 |
| Desaturation (SpO2 < 95%) | 6 (8.1) | 3 (8.1) | 3 (8.1) | 0.315 |
| Chest pain | 5 (6.7) | 3 (8.1) | 2 (5.4) | 0.500 |
| Respiratory failure | 0 (0.0) | 0 (0.0) | 0 (0.0) | ‐ |
| Death | 0 (0.0) | 0 (0.0) | 0 (0.0) | ‐ |
| Total cases | 7 (9.4) | 4 (10.8) | 3 (8.1) | 0.317 |
Significant differences (P < 0.05). R‐EBUS, radial endobronchial ultrasound; SpO2, peripheral oxygen saturation; TBB, transbronchial biopsy.